ClinicalTrials.gg

Program

HSK42360

A development code. Also written as “HSK42360-Na Tablets” and “HSK42360-Na”.

Its studies are mostly in Colorectal Neoplasms · Brain Neoplasms, led by Haisco Pharmaceutical Group.

Furthest: phase 2, since Aug 13, 20264 company-led studies, 4 open or runningNext primary completion: Dec 2, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Haisco Pharmaceutical Group44 open or runningphase 2since Aug 13, 2026Jul 24, 2024Dec 2, 2028phase 1 · NCT07561554

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 24, 2024First study: phase 1 study in Solid TumorsFirst studyNCT06536400 · 316 planned · China
  2. Aug 6, 2025Phase 1 study in Malignant Brain TumorsNCT07158710 · 159 planned · China
  3. Mar 23, 2026Phase 1 study in Solid Tumors (Phase 1)NCT07561554 · 159 planned · China
  4. Aug 13, 2026Phase 2 study in Colorectal NeoplasmsPhase 2 reachedNCT07790510 · 180 planned · China

Ahead

  1. Dec 2, 2028Primary completion: phase 1 study in Solid Tumors (Phase 1)NCT07561554
  2. May 23, 2029Primary completion: phase 1 study in Malignant Brain TumorsNCT07158710
  3. Sep 30, 2029Primary completion: phase 2 study in Colorectal NeoplasmsNCT07790510

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07790510Colorectal Neoplasms · China2RecruitingSep 30, 2029180
NCT07561554Solid Tumors (Phase 1) · China1RecruitingDec 2, 2028159
NCT07158710Malignant Brain Tumors · China1RecruitingMay 23, 2029159
NCT06536400Solid Tumors · China1RecruitingAug 30, 2026316

How it is read

Names in the registry

  • “HSK42360”, 2 entries
  • “HSK42360-Na Tablets”, 1 entry
  • “HSK42360-Na”, 1 entry

Codes read as this program: HSK42360.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.